XenoTherapeutics Presents Update on First Non-Human Transplant Technology

XenoTherapeutics, a life science company developing the first non-human organ transplant solution currently under investigational review by the FDA, announced that company co-founders Paul Holzer, CEO and Jon Adkins, COO presented an update on the company’s pre-clinical progress for its skin transplant solution at the 2018 Dan Morton Meeting of the Boston Area Pharmaceutical Toxicology Group. The conference, held today at the Novartis Institutes for BioMedical Research in Cambridge, hosted representatives from a variety of biotechnology companies on the cutting-edge of research and development